FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Wyoming News1d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
FiercePharma2d
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Pharm Exec2d
FDA Approves Johnson & Johnson’s Spravato for Treatment-Resistant Depression
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
Johnson & Johnson announces FDA approves sNDA for Spravato
Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this ...
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
mic1d
A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.